2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 46

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Abstract Number: 47

Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Abstract Number: 48

Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Abstract Number: 49

Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Abstract Number: 50

Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Abstract Number: 51

The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Abstract Number: 52

How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study
Abstract Number: 53

A Prospective Study to Assess for Changes in Mood with Initiation of Anti-TNF therapy: A Pilot Study
Abstract Number: 54

Treatment and 1-year outcomes of an inception cohort of Australian children with JIA
Abstract Number: 55

Celiac Disease in Children Diagnosed with Juvenile Idiopathic Arthritis
Abstract Number: 56

Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
Abstract Number: 57

Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis
Abstract Number: 58

Analysis and Implications of Non-Invasive Knee Acoustical Emissions in Juvenile Idiopathic Arthritis
Abstract Number: 59

Six Minute Walk Test in Children with Juvenile Idiopathic Arthritis
Abstract Number: 60

Paediatric Arthritis Rehabilitation Exercise Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].